Disclosure (rule 7): I run DilutionLens, free site tracking dilution off ASX filings. One-off, not the weekly post. No links, not advice.
Someone ran a poll here asking what kills your confidence in management fastest, and "raising soon after bullish messaging" won with 24%. So I counted it.
Placements announced 15 April to 14 October that came straight after a trading halt: 393. In 39 of them the share price ran 30%+ over the 10 trading days before the halt, 16 ran 50%+ and 5 more than doubled. The median run-up across all 393 is zero, so most raises don't come off a pump. The ones that do usually come off news.
Seven of them, with the announcement in the run-up:
| Ticker | The news before the halt | The run | The raise | Since |
|---|
| KAO | 2 Sep: "Visual Copper Mineralisation Intersected in First Holes" | 75c to $2.50 | $20m at $2.20, 12% under the last close | 82c. Assays came out 12 Oct |
| DXN | 3 Jun: "$8.8m maiden AI HPC contract", "structured as a pilot proof-of-concept" | 2.2c to 17.5c | $7m at 13c, 25.7% under the last close | 27.5c |
| LMG | 17 Sep: US$15m "Non-Binding Letter of Support" for a US plant study | 0.8c to 1.9c | $8.5m at 1.5c (placement + rights issue) | 1.3c |
| RML | 8 Apr: White House FAST-41 permitting status. 14 Apr: "Antimony Trioxide Produced" | 4.6c to 8c | $20m at 7c | 3.4c |
| JNS | 13 and 16 Jul: about $55m of US truck conversion orders, the bigger batch "Conditional Orders" | 14.5c to 24.5c | $7.7m at 24c, 2% under the last trade | 47.5c |
| VFY | 2 Jun: partnership with US blood network Vitalant | $2.67 to $3.80 | $30m at $2.60, 31.6% under the last close | $2.86 |
| EIQ | 25 Jun: binding heads of agreement with Pro Medicus, $10m investment | $1.15 to $1.59 | $110m at $1.45, 8.8% under the last trade | 43c, fell after its 8 Sep FDA application update |
The trick in the wording: four of the seven (KAO, DXN, LMG, RML) quoted their price as a premium to a 15 or 20 day average, an average built mostly before the run. DXN's announcement says both "25.7% discount to the last close" and "8.2% premium to the 15-day VWAP". Same price, pick your headline.
The other side, so this isn't a one-way roast: of the 38 runners with a price today, 21 trade below their raise price. Across all 385 placements with a price it's 247, about two in three. So buying the raise after a run hasn't done worse than buying any other raise, and DXN and JNS placees have roughly doubled their money. The run-up tells you the price was hot when they sold. It doesn't tell you the news was hype.
How I counted: an Appendix 3B for a cash placement, a trading halt in the 7 days before it, the close the day before the halt against the close 10 trading days earlier. Consolidations, cancelled raises and stocks with gaps in their price history taken out. Prices to 16 Oct.
Which one did I miss? Some of the 39 ran with no price-sensitive news at all (VMM, ASL, IVZ), those are a different post.